- Home
- CURX
as 10-29-2025 9:37am EST
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | JERICHO |
| Market Cap: | 29.7M | IPO Year: | 2025 |
| Target Price: | N/A | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $8.60 | Next Earning Date: | 09-09-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Curanex Pharmaceuticals Inc Common Stock News
CURX Breaking Stock News: Dive into CURX Ticker-Specific Updates for Smart Investing
Compare CURX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CURX Curanex Pharmaceuticals Inc Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.